Features Partner Sites Information LinkXpress
Sign In
Demo Company

New Approach Restores Effectiveness of Older Antibiotics

By BiotechDaily International staff writers
Posted on 29 Apr 2014
Print article
Image: Cultured bacteria showing increased sensitivity to antibiotics with the additional of a metallopolymer (Photo courtesy of University of South Carolina).
Image: Cultured bacteria showing increased sensitivity to antibiotics with the additional of a metallopolymer (Photo courtesy of University of South Carolina).
Methicillin-resistant Staphylococcus aureus (MRSA), a complex of multidrug-resistant Gram-positive bacterial strains, has proven especially problematic in both hospital and community settings.

These bacteria have become drug resistant by deactivating conventional β-lactam antibiotics, including penicillins, cephalosporins, and carbapenems.

Microbiologists at the University of South Carolina (Columbia, SC, USA) introduced a class of charged metallopolymers that exhibit synergistic effects against MRSA by efficiently inhibiting activity of β-lactamase and effectively lysing bacterial cells.

The β-lactam structure in a molecule is something that many bacteria are adverse to. It greatly hinders their ability to reproduce by cell division, and so chemists have for years spent time making molecules that all contain the β-lactam structural motif. One of the most effective bacterial defenses is an enzyme called β-lactamase, which chews up the β-lactam structure. Some bacteria, such as MRSA, have developed the ability to biosynthesize and release β-lactamase when needed. It is a devastating defense because it is so general, targeting the common structural motif in all of the many β-lactam antibiotics.

The interdisciplinary team also showed that the antimicrobial effectiveness of the four β-lactams studied in detail was enhanced by the polymer. They prepared a cobaltocenium metallopolymer that greatly slowed the destructiveness of β-lactamase on a model β-lactam molecule (nitrocefin). The enhancement was modest against two strains, but very pronounced with the hospital-associated strain of MRSA (HA-MRSA). The four antibiotics penicillin-G, amoxicillin, ampicillin, and cefazolin, were protected from β-lactamase hydrolysis via the formation of unique ion-pairs between their carboxylate anions and cationic cobaltocenium moieties.

The study was published on March 17, 2014, in the Journal of the American Chemical Society.

Related Links:

University of South Carolina

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.